Journal article
Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study
Abstract
Cost-effectiveness analyses are required for therapies within Canada's universal healthcare system, leading to delays relative to U.S. healthcare. Patients with Hodgkin lymphoma (HL) generally have an excellent prognosis, but those who relapse after or are ineligible for transplant benefit from novel therapies, including brentuximab vedotin (BV). BV was FDA-approved in 2011 but not Canadian-funded until 2014. To assess the impact of access …
Authors
Davies GA; Orav JE; Brantley KD
Journal
Current Oncology, Vol. 31, No. 7, pp. 3885–3894
Publisher
MDPI
DOI
10.3390/curroncol31070287
ISSN
1198-0052